Astellas to Buy Audentes in $3 Billion Gene-Therapy Deal

December 4, 2019

Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies.

Related Stories